WT1 peptide vaccination for patinets with hematological CR after induction chemotherapy

WT1 peptide vaccination for patinets with hematological CR after induction chemotherapy - WT1 peptide vaccination for patinets with hematological CR after induction chemotherapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017937

Enrollment

Registered

2015-06-17

Start date

2015-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer vaccine

Interventions

WT1 peptide + WT1 helper peptide with Montanide WT1 peptide + WT1 helper peptide + CpG with Montanide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hematological CR aftet induction chemotherapy 2. HLA0201 or 2402 3. PS0-1 and main organs are good status 4. Recovery of hematopoiesis

Exclusion criteria

Exclusion criteria: 1. double cancer 2. active infections 3. autoinflamatory disease

Design outcomes

Primary

Measure	Time frame
Safety of WT1 vaccine therapy before consloidation chemothrapy	—

Secondary

Measure	Time frame
2 year DFS or OS	—

Countries

Japan

Contacts

Public ContactHaruo Sugiyama

Osaka university Cancer immunotherapy

clinical-trial@cit.med.osaka-u.ac.jp+81-6-6879-3676

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026